Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.

The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

(RTTNews) - According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent reduced risk of HIV infection overall. The Phase III ...

Health experts say lenacapavir could reduce the number of global HIV infections significantly. It can protect against HIV with only two injections per year. But it needs to be cheaper to be effective.

Early trials have found that the antiretroviral treatment lenacapavir is 100 percent effective in preventing HIV infection. And it only needs to be injected twice a year, making the drug far easier to ...

Gilead Sciences has announced the outcomes from the randomised Phase III PURPOSE 2 trial evaluating lenacapavir for human immunodeficiency virus (HIV) prevention. The trial demonstrated a 96% ...

Geneva — Ahead of World AIDS Day, Unitaid is announcing a US$22 million investment to accelerate the introduction and access to lenacapavir, a revolutionary long-acting HIV prevention option.